Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Steven J. Hughes

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5688-6942; OpenAlex author ID A5032632922; NIH RePORTER profile ID 2083435. Sources: OpenAlex.

Their work

Papers
52 (first author 0, last author 20)
Trials
0
Grants
3
Labs led
1
Collaborators
95
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: 4 papers · 2016: 3 papers · 2017: 5 papers, 1 grant · 2018: 6 papers · 2019: 1 paper · 2020: 5 papers · 2021: 1 paper · 2022: 4 papers · 2023: 8 papers · 2024: 4 papers, 1 grant · 2025: 3 papers · 2026: 6 papers, 1 grant

Papers 50 of 52

  1. Neoadjuvant Radiation is Causally Linked to Increased Operative Time and Perioperative Blood Transfusion in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.jss.2026.01.031↗
  2. Towards early detection of pancreatic cancer: The current status of cohort studies by the Diabetes-Pancreatic Ductal AdenoCarcinoma Working Group. Last author DOI 10.1016/j.pan.2026.04.020↗
  3. Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial. Last author DOI 10.1093/oncolo/oyag250↗
  4. The Rising Burden of Premature Mortality Due to Pancreatic Cancer in the United States. Last author DOI 10.1097/mpa.0000000000002653↗
  5. Neoadjuvant Therapy for Localized Pancreatic Cancer. Co-author DOI 10.3390/cancers18061011↗
  6. Pancreatoblastoma: A Descriptive and Comparative Analysis with Pancreatic Ductal Adenocarcinoma Using SEER Data. Co-author DOI 10.3390/cancers18162642↗
  7. Oncologic Efficacy of Robotic Compared to Open Total Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.1016/j.jss.2024.10.043↗
  8. A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. Last author DOI 10.1016/j.neo.2024.101070↗
  9. Nanomaterial isolated extracellular vesicles enable high precision identification of tumor biomarkers for pancreatic cancer liquid biopsy. Co-author DOI 10.1186/s12951-025-03527-3↗
  10. Heterogeneity of weight loss and transcriptomic signatures in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jcsm.13390↗
  11. Variability of quality-of-life measurements and reporting in randomised controlled trials of pancreatic cancer: a systematic review. Last author DOI 10.1136/bmjopen-2023-083696↗
  12. Fibroblasts in the Aged Pancreas Drive Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-24-0086↗
  13. Infiltration of CD3+ and CD8+ lymphocytes in association with inflammation and survival in pancreatic cancer. Last author DOI 10.1371/journal.pone.0297325↗
  14. A peek at the other side of the coin: Tumor-suppressor role of microRNAs expressed by pancreatic cancer-associated fibroblasts. Co-author DOI 10.1002/ctm2.1357↗
  15. Impact of Biopsy Attempts, Race, and Access on Time to Initiation of Treatment for Pancreatic Cancer. Last author DOI 10.1007/s11605-022-05531-6↗
  16. National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. Last author DOI 10.1016/j.hpb.2023.06.018↗
  17. A protein-based machine learning approach to the identification of inflammatory subtypes in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2023.06.007↗
  18. Ethical Considerations of Biopsies in Early-Stage Pancreatic Cancer. Co-author DOI 10.1200/op.23.00044↗
  19. A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. Co-author DOI 10.2217/fon-2023-0256↗
  20. Changing Practice Patterns and Improving Survival for Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15184464↗
  21. Translocation of Oral Microbiota into the Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Co-author DOI 10.3390/microorganisms11061466↗
  22. The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.neo.2022.100789↗
  23. The oral microbiome, pancreatic cancer and human diversity in the age of precision medicine. Co-author DOI 10.1186/s40168-022-01262-7↗
  24. From bench to bedside: Pursuing equity in precision medicine approaches to pancreatic cancer care. Co-author DOI 10.3389/fonc.2022.1086779↗
  25. Single-cell profiling of microenvironment components by spatial localization in pancreatic ductal adenocarcinoma. Last author DOI 10.7150/thno.73222↗
  26. Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1002/onco.13853↗
  27. From tumor microenvironment communicants to biomarker discovery: Selectively packaged extracellular vesicular cargoes in pancreatic cancer. Last author DOI 10.1016/j.cytogfr.2020.01.001↗
  28. Protein Signatures and Tissue Diagnosis of Pancreatic Cancer. Last author DOI 10.1016/j.jamcollsurg.2019.10.002↗
  29. Unique circulating immune signatures for recurrent acute pancreatitis, chronic pancreatitis and pancreatic cancer: A pilot study of these conditions with and w… Co-author DOI 10.1016/j.pan.2019.11.008↗
  30. The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsi… Co-author DOI 10.1111/apt.15698↗
  31. Nicotine Induces IL-8 Secretion from Pancreatic Cancer Stroma and Worsens Cancer-Induced Cachexia. Co-author DOI 10.3390/cancers12020329↗
  32. The Proteome of Pancreatic Cancer-Derived Exosomes Reveals Signatures Rich in Key Signaling Pathways. Last author DOI 10.1002/pmic.201800394↗
  33. Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. Co-author DOI 10.1007/s12029-017-0021-z↗
  34. A Prospective Study to Establish a New-Onset Diabetes Cohort: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001169↗
  35. PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies: Rationale and Study Design for PROCEED From the Consortium for the … Co-author DOI 10.1097/mpa.0000000000001170↗
  36. Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pan… Co-author DOI 10.1097/mpa.0000000000001171↗
  37. Stroma-derived extracellular vesicles deliver tumor-suppressive miRNAs to pancreatic cancer cells. Last author DOI 10.18632/oncotarget.23532↗
  38. Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine. Co-author DOI 10.3390/ijms19123836↗
  39. A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2016.09.038↗
  40. Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Huma… Co-author DOI 10.1097/mpa.0000000000000843↗
  41. Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. Co-author DOI 10.1158/0008-5472.can-16-1765↗
  42. Human pancreatic cancer xenografts recapitulate key aspects of cancer cachexia. Co-author DOI 10.18632/oncotarget.13593↗
  43. Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer. Co-author DOI 10.4240/wjgs.v9.i4.103↗
  44. Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. Co-author DOI 10.1016/j.ajpath.2016.02.009↗
  45. Targeting tumor tolerance: A new hope for pancreatic cancer therapy? Last author DOI 10.1016/j.pharmthera.2016.06.008↗
  46. Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-15-1256↗
  47. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Co-author DOI 10.1002/cam4.444↗
  48. Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in hum… Last author DOI 10.1007/s00262-015-1760-y↗
  49. Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. Co-author DOI 10.1016/j.ajpath.2015.01.016↗
  50. The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. Last author DOI 10.1186/s12885-015-1820-x↗

Grants 3

  1. The Chronic Pancreatitis Clinical Research Consortium U01DK144420↗
  2. U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS U01DK108320↗
  3. Protein Signatures Improve the Diagnostic Yield of Fine Needle Aspiration AWARD pancan:2017-steven-hughes-protein-signatures-improve-the-diagnosti

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christopher E Forsmark · 8 shared papers, 2 shared grants, 2018–2026 · strength 2.93
  2. Song Han · 18 shared papers, 2015–2026 · strength 2.80
  3. Kelly M. Herremans · 14 shared papers, 2022–2026 · strength 2.77
  4. Thomas J. George · 20 shared papers, 2015–2026 · strength 2.56
  5. Jose Gilberto Trevino · 22 shared papers, 2015–2026 · strength 2.51
  6. Ibrahim Nassour · 11 shared papers, 2022–2026 · strength 2.43
  7. Andrea N. Riner · 12 shared papers, 2022–2026 · strength 2.32
  8. Patrick W. Underwood · 11 shared papers, 2018–2026 · strength 1.88
  9. Gerik W. Tushoski-Alemán · 8 shared papers, 2022–2026 · strength 1.72
  10. Jordan A. McKean · 5 shared papers, 2025–2026 · strength 1.48
  11. Daniel Delitto · 14 shared papers, 2015–2024 · strength 1.04
  12. Alessandro Paniccia · 4 shared papers, 2023–2026 · strength 1.03
  13. Richard E Pratley · 1 shared grant, 2026 · strength 1.00
  14. Ryan Michael Thomas · 11 shared papers, 2015–2026 · strength 0.93
  15. Kathryn E. Hitchcock · 5 shared papers, 2017–2026 · strength 0.88
  16. Jesus C. Fabregas · 4 shared papers, 2023–2026 · strength 0.82
  17. Kenneth Cusi · 1 shared grant, 2024 · strength 0.72
  18. Michael H. Gerber · 8 shared papers, 2017–2022 · strength 0.68
  19. Andrew R. Judge · 7 shared papers, 2017–2024 · strength 0.68
  20. Sarah M. Judge · 6 shared papers, 2017–2024 · strength 0.56
  21. Sherise Chantell Rogers · 3 shared papers, 2023–2026 · strength 0.56
  22. Abdul Qahar Khan Yasinzai · 2 shared papers, 2026 · strength 0.55
  23. Riley P. Bohan · 3 shared papers, 2022–2023 · strength 0.55
  24. Vignesh Vudatha · 3 shared papers, 2022–2024 · strength 0.53
  25. Shannon Margaret Wallet · 9 shared papers, 2015–2018 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.